NRGGI004
OPEN TO ACCRUAL
Ph 3 mFOLFOX6/Bevacizumab/Atezolizumab vs. Atezolizumab in dMMR/MSI-H Metastatic Colorectal Cancer
NRGGI008
OPEN TO ACCRUAL
II/III Study of Colon Adjuvant Chemo Based on Eval of Residual Disease (CIRCULATE-NORTH AMERICA)
UW20038
OPEN TO ACCRUAL
PhII Trial of Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients with mCRC
UW23016
OPEN TO ACCRUAL
Phase II Liposomal Irinotecan w/ TAS102 & Bevacizumab for Patients w/ mCRC